modelR05DB12
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | BibenzoniumBromide | |
| ATC code: | R05DB12 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Bibenzonium bromide is a quaternary ammonium compound classified as an antitussive, used for the treatment of cough. It acts as a peripheral antitussive agent, likely by suppressing the cough reflex through local action in the respiratory tract. It is not widely approved or currently used in most countries.
Pharmacokinetics
No published pharmacokinetic data for bibenzonium bromide in humans was found. The following parameters are rough estimates based on related quaternary ammonium antitussives.
References
Tytgat, GN (2007). Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67(9) 1343–1357. DOI:10.2165/00003495-200767090-00007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17547475
Mozaffari, S, et al., & Abdollahi, M (2018). Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert opinion on pharmacotherapy 19(10) 1127–1135. DOI:10.1080/14656566.2018.1491549 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29979903
Guirguis-Blake, JM, et al., & Whitlock, EP (2016). Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 315(13) 1378–1393. DOI:10.1001/jama.2016.2654 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27046366
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)